全文获取类型
收费全文 | 7676篇 |
免费 | 343篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 104篇 |
儿科学 | 150篇 |
妇产科学 | 102篇 |
基础医学 | 978篇 |
口腔科学 | 167篇 |
临床医学 | 417篇 |
内科学 | 1869篇 |
皮肤病学 | 226篇 |
神经病学 | 624篇 |
特种医学 | 281篇 |
外科学 | 1439篇 |
综合类 | 47篇 |
一般理论 | 1篇 |
预防医学 | 201篇 |
眼科学 | 144篇 |
药学 | 338篇 |
中国医学 | 12篇 |
肿瘤学 | 955篇 |
出版年
2023年 | 28篇 |
2022年 | 72篇 |
2021年 | 129篇 |
2020年 | 83篇 |
2019年 | 101篇 |
2018年 | 136篇 |
2017年 | 109篇 |
2016年 | 171篇 |
2015年 | 202篇 |
2014年 | 204篇 |
2013年 | 309篇 |
2012年 | 467篇 |
2011年 | 518篇 |
2010年 | 314篇 |
2009年 | 235篇 |
2008年 | 472篇 |
2007年 | 478篇 |
2006年 | 515篇 |
2005年 | 488篇 |
2004年 | 509篇 |
2003年 | 524篇 |
2002年 | 477篇 |
2001年 | 118篇 |
2000年 | 100篇 |
1999年 | 112篇 |
1998年 | 123篇 |
1997年 | 114篇 |
1996年 | 87篇 |
1995年 | 82篇 |
1994年 | 69篇 |
1993年 | 62篇 |
1992年 | 59篇 |
1991年 | 50篇 |
1990年 | 43篇 |
1989年 | 59篇 |
1988年 | 49篇 |
1987年 | 43篇 |
1986年 | 29篇 |
1985年 | 27篇 |
1984年 | 23篇 |
1983年 | 22篇 |
1982年 | 22篇 |
1981年 | 26篇 |
1980年 | 21篇 |
1979年 | 17篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1975年 | 17篇 |
1971年 | 13篇 |
1967年 | 11篇 |
排序方式: 共有8055条查询结果,搜索用时 17 毫秒
91.
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha 总被引:2,自引:0,他引:2
Sumigama S Ito T Kajiyama H Shibata K Tamakoshi K Kikkawa F Williams T Tainsky MA Nomura S Mizutani S 《Oncogene》2004,23(32):5496-5504
A previous report demonstrated that AP-2alpha favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2alpha in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2alpha in SKOV3 human ovarian cancer cells, which originally possess little AP-2alpha. AP-2alpha overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2alpha-overexpressing cells survived longer than those with neo-transfected cells. The present data represent the first direct evidence that AP-2alpha plays a tumor suppressive role in ovarian cancer. 相似文献
92.
Efficacy of combination therapies of percutaneous or laparoscopic ethanol-lipiodol injection and radiofrequency ablation 总被引:3,自引:0,他引:3
Kurokohchi K Masaki T Miyauchi Y Hosomi N Yoneyama H Yoshida S Himoto T Deguchi A Nakai S Inoue H Watanabe S Kuriyama S 《International journal of oncology》2004,25(6):1737-1743
Percutaneous radiofrequency ablation (RFA) is able to destroy hepatocellular carcinoma (HCC) in a few sessions without major complications. We have previously shown that not only the combined use of percutaneous ethanol injection and RFA (PEI-RFA) but also injection of mixture of ethanol and lipiodol (PELIT) was useful for the treatment of HCC. In the present study, we further developed the combined use of PELIT and RFA through percutaneous or laparoscopic approach (PELI-RFA or LELI-RFA) and evaluated its usefulness. Nineteen nodules in 18 cases were treated with PELI-RFA or LELI-RFA. In the cases treated with LELI-RFA, no bleeding and no spilling milky fluid containing tumor cells were observed from the surface of ablated tumors. In the cases sufficiently treated with PELI-RFA or LELI-RFA, the mixture of ethanol and lipiodol was accumulated in the entire region of the tumor and low-density area was observed around the lipiodol deposit by computed tomography (CT). These delineations of coagulated area were helpful to evaluate the precise area of safety margin around the tumor treated with PELI-RFA or LELI-RFA. Furthermore, the total volume of coagulated necrosis significantly and positively correlated with the product of energy requirement for ablation and the volume of ethanol injected by PELI-RFA or LELI-RFA. Among the cases treated with PELI-RFA or LELI-RFA, local recurrence emerged only in one case in whom enough safety margin could not be achieved by PELI-RFA. Therefore, it is critical to evaluate whether enough safety margin could be obtained with RFA therapy, and PELI-RFA and LELI-RFA are helpful in visualizing the safety margin area. 相似文献
93.
Treatment of acquired a plastic anemia: an update 总被引:1,自引:0,他引:1
Kojima S 《[Rinshō ketsueki] The Japanese journal of clinical hematology》2004,45(3):202-208
94.
Ohga S Mugishima H Ohara A Kojima S Fujisawa K Yagi K Higashigawa M Tsukimoto I;Aplastic Anemia Committee Japanese Society of Pediatric Hematology 《International journal of hematology》2004,79(1):22-30
The epidemiology and treatment outcomes for Diamond-Blackfan anemia (DBA) were surveyed in a cohort of 54 children (M/F = 26:28) registered in Japan from 1988 to 1998. The annual incidence was 4.02 cases per million births, the median age at diagnosis was 60 days, and 59% of the cases presented by 3 months of age. Three patients had a familial occurrence. All patients received prednisolone (PSL), and cyclosporin A (CsA) was added to the therapy in 17 patients. Forty-seven patients received transfusions, and 13 underwent hematopoietic stem cell transplantation (HSCT). The cumulative probabilities of a medication-free or a transfusion-free state prior to HSCT were 36% and 69%, respectively, at more than 5 years after diagnosis. Thirteen patients were weaned from PSL therapy without HSCT, and CsA was not associated with weaning from therapy. Transfusion and medication were stopped at 249 days and 933 days after diagnosis in 34 and 13 patients, respectively, who achieved a state of independence. No initial findings predicted the treatment dependence. More than 20% of patients experienced sustained hemosiderosis and/or adverse effects of PSL. The ages and reticulocyte counts at diagnosis of the patients who underwent HSCT were lower than in the patients who did not. HSCT led to the highest success (85%) of all previous reports, even though 5 alternative donors were included in our study. Two cord blood transplants from unrelated donors failed. These findings suggest the need for developing an integral treatment strategy including selective HSCT for refractory DBA. 相似文献
95.
96.
97.
Onitsuka S Akashi H Tayama K Okazaki T Ishihara K Hiromatsu S Aoyagi S 《The Annals of thoracic surgery》2004,78(4):1268-1273
Background
The purpose of this study was to examine the long-term outcome and the prognostic predictors related to the development of complications associated with acute type B aortic dissection.Methods
Seventy-six medically treated patients with acute type B aortic dissection were examined between 1990 and 2001. The events associated with aortic dissection included dissection-related death, rupture, visceral ischemia, lower limb ischemia, an increase in the maximum aortic diameter greater than 50 mm, and a mean enlargement rate of greater than 5 mm per year.Results
Among the 76 patients 10 (13%) underwent chronic phase surgery and 25 (33%) presented with an event. A statistically significant difference was observed between patients with and without events with regard to atherosclerotic factors, blood flow status in the false lumen, maximum aortic diameter upon admission, mean aortic enlargement rate, and blood pressure control during follow-up. Of these factors a patent false-lumen and a maximum aortic diameter greater than 40 mm upon admission were the most strongly associated factors with regard to the development of events. Patients with a patent false-lumen and a maximum aortic diameter greater than 40 mm upon admission were determined to exhibit significantly higher event rates than other patients.Conclusions
In determining the appropriate therapeutic approach for acute type B aortic dissection, it is important to pay careful attention to the predictors of a patent false-lumen and a maximum aortic diameter greater than 40 mm at onset to improve the long-term outcome. 相似文献98.
99.
Autoantibodies frequently detected in patients with aplastic anemia 总被引:22,自引:5,他引:17
Hirano N Butler MO Von Bergwelt-Baildon MS Maecker B Schultze JL O'Connor KC Schur PH Kojima S Guinan EC Nadler LM 《Blood》2003,102(13):4567-4575
Although accumulating evidence strongly suggests that aplastic anemia (AA) is a T cell-mediated autoimmune disease, no target antigens have yet been described for AA. In autoimmune diseases, target autoantigens frequently induce not only cellular T-cell responses but also humoral B-cell responses. We hypothesized that the presence of antigen-specific autoantibodies could be used as a "surrogate marker" for the identification of target T-cell autoantigens in AA patients. We screened a human fetal liver library for serologic reactivity against hematopoietic stem/progenitor cell antigens and isolated 32 genes. In 7 of 18 AA patients, an immunoglobulin G (IgG) antibody response was detected to one of the genes, kinectin, which is expressed in all hematopoietic cell lineages tested including CD34+ cells. No response to kinectin was detected in healthy volunteers, multiply transfused non-AA patients, or patients with other autoimmune diseases. Epitope mapping of IgG autoantibodies against kinectin revealed that the responses to several of the epitopes were shared by different AA patients. Moreover, CD8+ cytotoxic T cells raised against kinectin-derived peptides suppressed the colony formation of granulocyte macrophage colony-forming units (CFU-GMs) in an HLA class I-restricted fashion. These results suggest that kinectin may be a candidate autoantigen that is involved in the pathophysiology of AA. 相似文献
100.
High body mass index correlates with increased risk of venous irritation by vinorelbine infusion 总被引:7,自引:0,他引:7
Yoh K Niho S Goto K Ohmatsu H Kubota K Kakinuma R Nishiwaki Y 《Japanese journal of clinical oncology》2004,34(4):206-209
BACKGROUND: Vinorelbine is currently one of the most active chemotherapeutic agents. However, it is also a moderate vesicant that is well known to cause venous irritation and phlebitis. We conducted this study to identify clinical risk factors related to the incidence of venous irritation caused by peripheral vinorelbine infusion. METHODS: Medical records were used to investigate retrospectively a total of 201 cases of non-small cell lung cancer treated with a chemotherapeutic regimen containing vinorelbine. Venous irritation was evaluated in every course and graded according to the National Cancer Institute Common Toxicity Criteria version 2.0. Gender, age, body mass index (BMI), chemotherapeutic regimen, dose of vinorelbine and prior chemotherapy were used as clinical variables. RESULTS: A total of 928 vinorelbine infusions were administered to the 201 patients, among whom venous irritation occurred in 63 (31%). The incidence of venous irritation was 28% in the normal BMI (<25) group and 45% in the high BMI (25 or more) group and the difference between the two groups was statistically significant (P = 0.037). There were no significant correlations between the incidence of venous irritation and the clinical variables except BMI. In the multivariate analysis BMI was also a significant independent variable that correlated with increased risk of venous irritation (P = 0.017). CONCLUSIONS: Care is required when using vinorelbine to treat patients with a high BMI, especially with regard to the development of venous irritation. 相似文献